Question · asked by 1 review
Interferon-alpha (systemic) vs Placebo (subcutaneous): Safety of the intervention (adverse effects)
- Population
- People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
- Intervention
- Interferon-alpha (systemic)
- Comparison
- Placebo (subcutaneous)
- Outcome
- Safety of the intervention (adverse effects)
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Interferon-alpha (systemic) vs Placebo (subcutaneous) Safety of the intervention including adverse effects · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane All outcomes | Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms. | 1 study · 50 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes | 2013-10 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.